BioXcel Therapeutics (BTAI) Shares Outstanding (2017 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Shares Outstanding (Entity) of $27.1 million for Q1 2026, up 395.15% year-over-year from $5.5 million in Q1 2025, and up 121.78% quarter-over-quarter from $12.2 million in Q4 2025.
BioXcel Therapeutics (BTAI) Shares Outstanding (2017 - 2026) Analysis & Trends
BioXcel Therapeutics' Shares Outstanding (Entity) history runs 10 years deep, the most recent figure standing at $27.1 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 395.15% year-over-year to $27.1 million; the TTM figure through Mar 2026 stood at $27.1 million (up 395.15% YoY), while the FY2025 annual figure was $12.2 million, up 381.58% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $27.1 million, up from $12.2 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $27.1 million in Q1 2026, with the low at $1.7 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $2.1 million (2024), against an average of $5.3 million.
- The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Entity) rose 0.15% in 2022, then jumped 434.92% in 2025.
- BioXcel Therapeutics' Shares Outstanding (Entity) stood at $1.8 million in 2022, then advanced by 6.33% to $1.9 million in 2023, then surged by 35.52% to $2.5 million in 2024, then surged by 381.58% to $12.2 million in 2025, then jumped by 121.78% to $27.1 million in 2026.
- Business Quant data shows BTAI's Shares Outstanding (Entity) at $27.1 million in Q1 2026, $12.2 million in Q4 2025, and $14.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 4.44 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 1.17 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 417.60 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.58 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 42.60 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 1.16 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 101.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 499.50 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 832.44 Mn |
| 10 | BioXcel Therapeutics | 24.25 Mn | 24.25 Mn | 160,000.00 | 30.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.30 Mn |
| Mar 31, 2026 | 23.57 Mn |
| Dec 31, 2025 | 12.21 Mn |
| Sep 30, 2025 | 14.20 Mn |
| Jun 30, 2025 | 7.84 Mn |
| Mar 31, 2025 | 4.83 Mn |
| Dec 31, 2024 | 2.54 Mn |
| Sep 30, 2024 | 2.65 Mn |
| Jun 30, 2024 | 2.52 Mn |
| Mar 31, 2024 | 1.93 Mn |
| Dec 31, 2023 | 1.82 Mn |
| Sep 30, 2023 | 1.83 Mn |
| Jun 30, 2023 | 1.82 Mn |
| Mar 31, 2023 | 1.79 Mn |
| Dec 31, 2022 | 1.75 Mn |
| Sep 30, 2022 | 1.75 Mn |
| Jun 30, 2022 | 1.75 Mn |
| Mar 31, 2022 | 1.75 Mn |
| Dec 31, 2021 | 1.65 Mn |
| Sep 30, 2021 | 1.75 Mn |